JWJeffrey C. Wang

Jeffrey C. Wang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jeffrey C. Wang has a total of 115 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Comparison of operating field sterility in open versus minimally invasive microdiscectomies of the lumbar spine

    by DanielC Lu, CharlesH Li, AndrewY Yew, JonA Kimball, DuncanQ McBride, JeffC Wang

    Postoperative wound infection is a preventable risk that can lead to significant adverse outcomes and increased cost of care. Minimally invasive surgeries (MIS) have been found to have lower rates of postoperative infection compared with the traditional approach. To assess if the reported difference is related to intraoperative contamination or to other factors, we assessed the surgical field for sterility. We compared 10 MIS versus 10 traditional microdiscectomies. Swabs of the operating field were obtained before and after the procedure from multiple sites in the operating room. Positive and negative controls were taken of the skin immediately before and after preparation of the incision site. All swabs were plated out on Columbia blood agar plates and grown for 48 hours. Colony counting was performed to determine growth. There was no statistically significant difference in the colony counts of swab sites in traditional microdiscectomies compared with MIS microdiscectomies. There was no significant contamination of the operating field using either approach. In this prospective study, we found that there was no significant difference in bacterial counts in swabs of operative sites in either traditional or MIS microdiscectomies, suggesting that the decreased rate of postoperative infection in the reported literature for MIS cases may be related to other factors, such as patient selection and/or postoperative care.


  • Do Lumbar Motion Preserving Devices Reduce the Risk of Adjacent Segment Pathology Compared With Fusion Surgery? A Systematic Review

    by Jeffrey C. Wang, Paul M. Arnold, Jeffrey T. Hermsmeyer, Daniel C. Norvell

    A systematic review of the literature. To compare total disc replacement (TDR) with fusion, other motion-sparing devices with fusion, and motion-sparing devices with other motion-sparing devices to determine which devices may be associated with a lower risk of radiographical or clinical adjacent segment pathology (ASP). Adjacent segment pathology, also termed adjacent segment disease (ASD) or adjacent segment degeneration, is a controversial phenomenon that can occur after a spinal fusion; it is thought to be either related to the altered mechanics or loss of motion from the fusion or to be part of the natural history of progressive arthritis. Motion preservation devices theoretically may decrease or prevent ASP from occurring. A systematic search was conducted in PubMed and the Cochrane Library for literature published between January 1990 and February 2012. For all key questions, we identified all cohort studies and randomized controlled trials, making the comparison of interest independent of the outcomes measured. We searched each full-text article to determine whether it reported any type of structural or degenerative condition specifically occurring at an adjacent segment. We included articles reporting adult lumbar patients who had degenerative disc disease, disc herniation, radiculopathy, kyphosis, scoliosis, and spondylolisthesis, and who were treated with TDR, other motion-sparing procedures, or fusion. The overall strength of the evidence for each key question was rated using the Grades of Recommendation Assessment, Development and Evaluation (GRADE) criteria. There is moderate evidence to suggest that patients who undergo fusion may be nearly 6 times more likely to be treated for ASP than those who undergo TDR. From 2 randomized trials, the pooled risk of clinical ASP treated surgically was 1.2% and 7.0% in the TDR and fusion groups, respectively (P = 0.009). The increased risk of clinical ASP treated surgically associated with fusion is 5.8%. For every 17 operations, one might expect a new clinical ASP event requiring surgery when treated with fusion in those otherwise not harmed by TDR. There was insufficient literature to answer the other key questions, resulting in low to insufficient evidence that other motion-sparing operations are superior to fusion in preventing clinical ASP. There does seem to be a low rate of ASP after lumbar spinal fusion. The evidence suggests that the risk of clinical ASP following fusion is higher when compared with TDR, but there is limited evidence that fusion may increase the risk of developing clinical ASP compared with other motion-sparing procedures. 1. Evidence demonstrates that the risk of clinical ASP requiring surgery is likely greater after fusion but the risk is still quite rare. The increased risk compared to TDR could be as small as less than 1% or as great as 10%. Strength of Statement: Weak. 2. There is insufficient evidence to make a definitive statement regarding fusion versus other motion-sparing devices with respect to the risk of ASP.


  • What’s New in Spine Surgery

    by Keith H. Bridwell, Paul A. Anderson, Scott D. Boden, Alexander R. Vaccaro, Jeffrey C. Wang


  • Open Access

    A New Beginning

    by Jeffrey C. Wang

  • Open Access

    Is posterior fusion necessary with laminectomy in the cervical spine?

    by BeckD McAllister, BrandonJ Rebholz, JefferyC Wang

    Background: Cervical decompressive laminectomy is a common procedure for addressing multilevel cervical spine pathology. The most common reasons for performing simultaneous posterior cervical fusion include the prevention of progressive postlaminectomy kyphotic deformity or other types of instability which can contribute to late neurological deterioration. Methods: The medical literature (Pub Med with MeSH) concerning cervical laminectomy, posterior cervical fusion, and complications of laminectomy/fusion was reviewed. Additionally, references from the articles were queried to find additional literature. Results: Multiple studies concluded that cervical laminectomy versus laminectomy and fusion produced similar short-term postoperative outcomes. Careful patient selection was warranted to minimize the complications associated with cervical laminectomy alone; these included postoperative kyphosis (6-46%) and late deterioration (10-37%). The addition of a posterior cervical fusion was associated with relatively low complication rates, and avoided the evolution of late deformity or delayed neurological deterioration. Conclusion : Although the short-term results of cervical laminectomy versus laminectomy and fusion are similar, there appear to be more complications associated with performing laminectomy alone over the long term. Here, we reviewed the pros and cons of posterior cervical decompression alone versus decompression with fusion/instrumentation to treat cervical pathology, highlighting the complications associated with each surgical alternative.


  • Whatʼs New in Spine Surgery

    by Keith H Bridwell, Paul A Anderson, Scott D Boden, Alexander R Vaccaro, Jeffrey C Wang

    In postmenopausal women who have been receiving long-term treatment with bisphosphonates, is there an increased risk for subtrochanteric or femoral shaft fractures? Population-based nested case-control study with 7-year follow-up. Ontario, Canada. Cases were patients hospitalized with a subtrochanteric or femoral shaft fracture. The cases were drawn from a cohort of 205,466 women who were ≥68 years of age from Ontario, Canada, who initiated treatment with an oral bisphosphonate (alendronate, risedronate, or etidronate) between April 1, 2002, and March 31, 2008. Cases were matched to as many as 5 controls with no such fracture. Control patients were matched to case patients according to age and cohort entry period. Study participants were followed up to March 31, 2009. Exclusion criteria were any history of cancer in the preceding ten years; conditions associated with altered bone integrity, such as osteomalacia, osteopetrosis, hyperparathyroidism, hypercalcemia, epilepsy, celiac disease, Paget disease, renal osteodystrophy, or gastric bypass in the previous five years; or treatment with raloxifene, calcitonin, sodium fluoride, clodronate, pamidronate, or zoledronic acid in the preceding year. Participants were categorized as long-term users (≥5 years of therapy), intermediate users (three to five years of therapy), or short-term users (100 days to three years of therapy) of bisphosphonates. These exposure groups were compared with a reference group of transient (5 years. The association of cumulative doses of three to five years and 100 days to three years was also examined. A secondary analysis examined the association between bisphosphonate use and typical femoral neck or intertrochanteric hip fracture associated with osteoporosis. Over the 7-year study period, 716 women (0.35%) treated with bisphosphonates had a subtrochanteric or femoral shaft fracture. Use of bisphosphonates for ≥5 years was associated with an increased risk for hospitalization for a subtrochanteric or femoral shaft fracture compared with transient use of bisphosphonates (Table). Intermediate or short-term use was not associated with increased risk (Table). In the secondary analysis, 9723 women had an intertrochanteric or femoral neck fracture. Prolonged bisphosphonate use was associated with reduced overall risk for these fractures (adjusted odds ratio, 0.76; 95% confidence interval, 0.63-0.93). Intermediate bisphosphonate use was associated with a borderline reduced risk for fracture associated with osteoporosis and short-term use was associated with a nonsignificant reduction (Table). Postmenopausal women who have been receiving bisphosphonate therapy for ≥5 years had an increased risk for subtrochanteric or femoral shaft fractures.


  • Full-Length spp24, but Not Its 18.5-kDa Proteolytic Fragment, Inhibits Bone-Healing in a Rodent Model of Spine Fusion

    by Chananit Sintuu, Robert J. Simon, Masashi Miyazaki, Yuichiro Morishita, Henry J. Hymanson, Cyrus Taghavi, Elsa J. Brochmann, Samuel S. Murray, Jeffrey C. Wang

    Background: Growth factors like bone morphogenetic protein (BMP) are used as bone-graft substitutes to enhance bone growth in clinical situations. However, adverse reactions have been associated with BMP use. We developed a synthetic adjuvant therapy based on the sequence of a BMP-binding protein, secreted phosphoprotein-24 (spp24), which enhances the effects of BMPs and ameliorates the adverse reactions. Our hypothesis is that a natural proteolytic fragment of spp24 is identical to an osteogenic protein previously described independently by two investigators. To test this hypothesis, spp24 and a truncated form of spp24 were separately implanted with recombinant human BMP-2 (rhBMP-2) in a rodent model of spine fusion. Methods: Two isoforms of spp24 were constructed with use of DNA recombinant technology. Spp24 with or without rhBMP-2 were added to collagen sponges and implanted bilaterally between L4 and L5 transverse processes. Radiographs were made biweekly, and spines were explanted after eight weeks. Gross evaluation, microquantitative computed tomography study, and histological analysis were performed to evaluate bone growth. Results: Animals that received full-length spp24 and rhBMP-2 exhibited a complete obliteration of bone growth, while animals with the truncated form in combination with rhBMP-2 exhibited a mild inhibition to bone growth, with bone area measured from radiographs. Manual assessment and gross evaluation of all spines confirmed the results obtained from the bone-area measurements. Microquantitative computed tomography provided three-dimensional visual images of representative specimens, while histological staining of spine tissue displayed cellular evidence of bone formation. Conclusions: Results from this investigation confirm that the various isoforms of spp24 affect the bone-healing activity of rhBMP-2 in the rat spine fusion model. Thus, proteolytic modification of this protein is a likely mechanism for the regulation of BMP availability in the physiological environment. Future studies will define the roles of these proteins in controlling the activity of BMPs and other members of the transforming growth factor-beta family of cytokines. This information will increase the understanding of normal bone-healing, allowing for the engineering of more effective orthopaedic treatment.


  • Commentary: Gene therapy for spinal fusion

    by Jeffrey C. Wang


  • Lumbar Disk Herniation and Degenerative Disk Disease in Athletes

    by Payam Moazzaz, Jeffrey C. Wang

  • Open Access

    Enhancement of recombinant human BMP-7 bone formation with bmp binding peptide in a rodent femoral defect model

    by Jen-Chung Liao, Shiau-Tzu Tzeng, Gun Keorochana, Kwang-Bok Lee, Jared S. Johnson, Yuichiro Morishita, Samuel S. Murray, Jeffrey C. Wang

    Bone morphogenetic binding peptide (BBP) is an 18.5 kDa fragment of a bone matrix protein peptide. A rat femoral defect model was used to test the effect of BBP combined with recombinant human bone morphogenetic protein-7 (rhBMP-7) to induced bone healing. Two doses of BBP (500 and 1000 µg) were tested with two doses of rhBMP-7 (2 and 5 µg), and the results were compared with a positive control (10 µg rhBMP-7). Bone healing was evaluated by radiology, manual palpation, microcomputed tomography, and histology. The high dose of 10 µg of rhBMP-7 resulted in a consistent 100% bone union rate and a mature histological appearance on histology, and was used as a positive control. When 1000 µg of BBP was combined with lower doses of BMP-7 (2 µg rhBMP-7 or 5 µg rhBMP-7) significant differences were seen in radiographic scores, manual palpation, and bone volume, when compared to 2 µg rhBMP-7 or 5 µg rhBMP-7 alone. The combination of 1000 µg of BBP and 5 µg rhBMP-7 also achieved 100% fusion rate, induced a larger amount of bone formation, and yielded similar maturity of bone marrow when compared with the high dosage 10 µg rhBMP-7 group. This study demonstrated that when combined together, BBP can enhance the bone healing of rhBMP-7. Improved healing imparted by the addition of BBP may result in lesser amounts of rhBMP-7 needed to achieve union in the clinical setting. © 2010 OrthopaedicResearchSociety.PublishedbyWileyPeriodicals, Inc.JOrthopRes29:753–759,2011